Here, we show that eEF2K/eEF2 activity and expression are modulated in primary proliferating CLL cells, aligning with the data from the mouse model, and propose that translation elongation is a novel therapeutic target in CLL, through inhibition of eEF2 activity [33, 39–41]. The gene discussed is EEF2K; the disease is B-cell chronic lymphocytic leukemia.